Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study
Our study underscores the importance of ADRs as a cause of missed doses of treatment, particularly hepatobiliary disorders. Regimens that are less prone to ADRs and strong healthcare system support structures for patients with ADRs are required to minimize missed doses, reducing unfavourable outcomes.
Authors
- Eleanor Dixon (ORCID: https://orcid.org/0000-0001-9697-0068)
- Līga Kukša
- Vija Riekstiņa
- Marisa D. Muckian (ORCID: https://orcid.org/0000-0003-0419-3797)
- Derek J. Sloan (ORCID: https://orcid.org/0000-0002-7888-5449)
- Evita Biraua
- James W. Dear (ORCID: https://orcid.org/0000-0002-8630-8625)
- Helen R. Stagg (ORCID: https://orcid.org/0000-0003-4022-3447)
- Edvards Brencsēns
- Vitālijs Pašuks
- Anete Šperberga
Institutions
- University of St Andrews (GB)
- HM Prison Service (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Riga East University Hospital (LV)
- University of Edinburgh (GB)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1002/bcp.70197
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medical Research Council